KYPROLIS (carfilzomib) for Injection Menu

Now With Overall Survival Data

When multiple myeloma relapses,

Don't put your patient's survival at risk1,2

KYPROLIS®-based regimens (KRd and Kd) reduced the risk of death by 21% vs Rd and Vd and extended median overall survival by 7.9 and 7.6 months, respectively.1,2,*,†,‡,§

KRdAs A Triplet Therapy

Superior

8.7-month increase in median PFS3

26.3 months (KRd) vs 17.6 months (Rd); hazard ratio (KRd/Rd) = 0.69 (95% CI: 0.57-0.83); two-sided P = 0.0001

7.9-month increase in median OS1

*48.3 months (KRd) vs 40.4 months (Rd); hazard ratio (KRd/Rd) = 0.79 (95% CI: 0.67-0.95)

Deep Response

>3x CR or better3

32% (KRd) vs 9% (Rd)

CI = confidence interval; CR = complete response;
KRd = KYPROLIS®, lenalidomide, and dexamethasone; OS = overall survival; PFS = progression-free survival; Rd = lenalidomide and dexamethasone.

The KRd vs Rd OS results have not yet been reviewed by FDA, and inclusion in the final, FDA-approved label for KYPROLIS® has yet to be determined.

K + Rd SEE KRd RESULTS See a video with multiple myeloma expert Dr. James Berenson

KRd vs Rd study: A phase 3, randomized, open-label, multicenter superiority study evaluated KYPROLIS® in combination with lenalidomide and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy. 792 patients were randomized in a 1:1 ratio (396 patients to KRd, 396 to Rd). Patients received their randomized study treatment in 28-day cycles until disease progression or unacceptable toxicity occurred. KYPROLIS® was discontinued after Cycle 18. The primary endpoint was progression-free survival (PFS); select secondary endpoints included overall survival (OS), overall response rate (ORR), duration of response (DoR), and safety. The significance level of the preplanned OS second interim analysis is determined by the O’Brien-Fleming type alpha spending function based on the number of OS events observed by the analysis time.3-5

KdAs A Doublet Therapy

Superior

9.3-month increase in median PFS3

18.7 months (Kd) vs 9.4 months (Vd); hazard ratio (Kd/Vd) = 0.53 (95% CI: 0.44-0.65); one-sided P < 0.0001

7.6-month increase in median OS2

47.6 months (Kd) vs 40.0 months (Vd); hazard ratio (Kd/Vd) = 0.79 (95% CI: 0.65-0.96); one-sided P = 0.01

CI = confidence interval; Kd = KYPROLIS® and dexamethasone;
OS = overall survival; PFS = progression-free survival;
Vd = VELCADE® (bortezomib) and dexamethasone

The Kd vs Vd OS results have not yet been reviewed by FDA, and inclusion in the final, FDA-approved label for KYPROLIS® has yet to be determined.

NCCN Guidelines®: Carfilzomib (KYPROLIS®) + dexamethasone is the only preferred doublet regimen for relapsed multiple myeloma3,6

Carfilzomib (KYPROLIS®) in combination with dexamethasone (Kd) has a category 1 designation in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma (Version 2.2018) for previously treated multiple myeloma.3,6

K + d SEE Kd RESULTS See a video with multiple myeloma expert Dr. Joshua Richter

§Kd vs Vd study: A phase 3, randomized, open-label, multicenter superiority study compared KYPROLIS® plus dexamethasone (Kd) to VELCADE® plus dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma who had received 1 to 3 lines of therapy. 929 patients were randomized to a 1:1 ratio to receive Kd (n = 464) for 28-day cycles or Vd (n = 465) for 21-day cycles until disease progression or unacceptable toxicity occurred. Patient stratification included prior proteasome inhibitor therapy (either VELCADE® or KYPROLIS®, or no prior therapy), prior lines of therapy (1 vs 2 or 3), International Staging System stage (1 vs 2 or 3), and planned route of VELCADE® administration, if randomized to the VELCADE® group (intravenous vs subcutaneous). The primary endpoint was progression-free survival (PFS). Select secondary endpoints included overall survival (OS), overall response rate (ORR), duration of response (DoR), and safety. The significance level of the preplanned OS second interim analysis is determined by the O’Brien-Fleming type alpha spending function based on the number of OS events observed by the analysis time. 3,7,8

NCCN Guidelines®: Carfilzomib (KYPROLIS®) + dexamethasone is the only preferred doublet regimen for relapsed multiple myeloma3,6

Carfilzomib (KYPROLIS®) in combination with dexamethasone (Kd) or with lenalidomide and dexamethasone (KRd) has a category 1 designation in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma (Version 2.2018) for previously treated multiple myeloma.3,6

NCCN Guidelines®: Carfilzomib (KYPROLIS®) + dexamethasone is the only preferred doublet regimen for relapsed multiple myeloma3,6

Carfilzomib (KYPROLIS®) in combination with dexamethasone (Kd) or with lenalidomide and dexamethasone (KRd) has a category 1 designation in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma (Version 2.2018) for previously treated multiple myeloma.3,6

KYPROLIS® dosing:
Add K to d or Add K to Rd

Kd 56 mg/m2 therapeutic dose
KRd 27 mg/m2 therapeutic dose
See KYPROLIS® Dosing

d = dexamethasone; K = KYPROLIS®;
Rd = lenalidomide and dexamethasone.

Safety profile

of KYPROLIS® regimens
(Kd and KRd) and treatment duration

SEE SAFETY PROFILE

Amgen Assist 360™:

Here to help your patients

Amgen Assist 360<sup>TM</sup> logo SEE SUPPORT

References

1. Data on file, Amgen; [1]; 2017. 2. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Overall survival of patients with relapsed or refractory multiple myeloma treated with carfilzomib and dexamethasone versus bortezomib and dexamethasone in the randomized phase 3 ENDEAVOR trial. Abstract presented at: 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India. Abstract. 3. KYPROLIS® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary. 4. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-152. 5. Data on file, Amgen; [2]; 2017. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2018. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed November 30, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN GUIDELINES, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 7. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38. 8. Data on file, Amgen; [3]; 2017. 3. KYPROLIS® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary. 4. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-152. 5. Data on file, Amgen; [2]; 2017. 3. KYPROLIS® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary. 4. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142-152. 5. Data on file, Amgen; [2]; 2017.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their applications or use in any way.
VELCADE® is a registered trademark of Millennium Pharmaceuticals, Inc.

Important Safety Information

Cardiac Toxicities

  • New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of KYPROLIS. Some events occurred in patients with normal baseline ventricular function. Death due to cardiac arrest has occurred within one day of KYPROLIS administration.
  • Monitor patients for clinical signs or symptoms of cardiac failure or cardiac ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold KYPROLIS for Grade 3 or 4 cardiac adverse events until recovery, and consider whether to restart KYPROLIS at 1 dose level reduction based on a benefit/risk assessment.
  • While adequate hydration is required prior to each dose in Cycle 1, monitor all patients for evidence of volume overload, especially patients at risk for cardiac failure. Adjust total fluid intake as clinically appropriate in patients with baseline cardiac failure or who are at risk for cardiac failure.
  • Patients ≥ 75 years, the risk of cardiac failure is increased. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or arrhythmias may be at greater risk for cardiac complications and should have a comprehensive medical assessment (including blood pressure and fluid management) prior to starting treatment with KYPROLIS and remain under close follow-up.

Acute Renal Failure

Tumor Lysis Syndrome

Pulmonary Toxicity

Pulmonary Hypertension

Dyspnea

Hypertension

Venous Thrombosis

Infusion Reactions

Hemorrhage

Thrombocytopenia

Hepatic Toxicity and Hepatic Failure

Thrombotic Microangiopathy

Posterior Reversible Encephalopathy Syndrome (PRES)

Increased Fatal and Serious Toxicities in Combination with Melphalan and Prednisone in Newly Diagnosed Transplant-ineligible Patients

Embryo-fetal Toxicity

Adverse reactions

Please see full Prescribing Information.

Indications